Home > Riviste > Minerva Gastroenterologica e Dietologica > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2019 March;65(1) > Minerva Gastroenterologica e Dietologica 2019 March;65(1):30-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   Freefree

Minerva Gastroenterologica e Dietologica 2019 March;65(1):30-5

DOI: 10.23736/S1121-421X.18.02530-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Oral administration of a lecithin-based delivery form of boswellic acids (Casperome®) for the prevention of symptoms of irritable bowel syndrome: a randomized clinical study

Antonella RIVA 1, Luca GIACOMELLI 2 , Stefano TOGNI 1, Federico FRANCESCHI 1, Roberto EGGENHOFFNER 2, Maria Chiara ZUCCARINI 3, Gianni BELCARO 3

1 Indena S.p.A, Milan, Italy; 2 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy; 3 IRVINE3 Vascular Lab and Physiology, Chieti-Pescara University, Pescara, Italy



BACKGROUND: The purpose of this study was to evaluate the long-term efficacy and the safety of a lecithin-based delivery form of boswellic acids from Boswellia serrata (Casperome®) for the prevention of symptoms in otherwise healthy subjects with mild irritable bowel syndrome (IBS).
METHODS: The study included 69 otherwise healthy participants with a mild form of IBS who completed a 6-month follow-up period. In total, 34 subjects were assigned to the standard management (SM) group: diet and, if needed, hyoscine butylbromide (Buscopan®) or papaverine hydrochloride + 10 mg of Atropa belladonna extract; 35 subjects were assigned to supplementation with the Boswellia serrata lecithin-based delivery form (one tablet/day; Casperome®). IBS signs and symptoms were evaluated at inclusion (T0), after 3 (T1) and 6 months (T2). The numbers of patients who needed rescue medication were recorded. Adverse events were also evaluated.
RESULTS: At baseline, the groups were comparable in terms of demographic and clinical characteristics. At follow-up, compared with the SM group, the Boswellia group showed lower mean score values for almost all self-assed IBS symptoms. A significantly lower need for rescue medications and consultations or medical evaluation/admissions was found in the Boswellia group compared with the SM group. The incidence of minimal adverse events - mainly stipsis - was significantly higher in the SM group. Oxidative stress at T2 was significantly decreased in Boswellia-supplemented subjects.
CONCLUSIONS: Boswellia serrata lecithin-based delivery form (Casperome®) appears to be effective and safe in improving signs and symptoms in IBS subjects who are otherwise healthy, particularly in comparison with symptomatic drug treatment that may cause side effects and stiptis.


KEY WORDS: Irritable bowel syndrome - Boswellia - Abdominal pain - Boswellic acid

inizio pagina